As of May 27, 2020, 5,612,601 people have been diagnosed with COVID-19 and 349,060
deaths have been recorded, with a mortality rate of up to 6.22% worldwide. Despite the …

Immune checkpoint inhibitors (ICIs) are used for the treatment of numerous cancers, but
risks associated with ICI-therapy during the COVID-19 pandemic are poorly understood. We …

By the beginning of the global pandemic, SARS-CoV-2 infection has dramatically impacted
on oncology daily practice. In the current oncological landscape, where immunotherapy has …

Introduction The COVID-19 pandemic occurred amid the cancer immunotherapy revolution.
Immune checkpoint inhibitors (ICIs) have become the standard of care for several solid …

Since December 2019, a novel coronavirus disease (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), initially reported in Wuhan, China …

Effects of initiation of programmed-death-protein 1 (PD1) blockade during active SARS-CoV-
2 infection on antiviral immunity, COVID-19 course, and underlying malignancy are unclear …

Immune checkpoint inhibitors (ICI) have become the standard of care treatment for several
tumor types. ICI-induced pneumonitis is a serious complication seen with treatment with …

Background Checkpoint inhibitor-related pneumonitis (CIP) is not well classified according
to clinical factors. We propose different clinical sub-types of CIP based on clinical factors and …

Dear Editor, Identifying risk factors of severe manifestation and unfavourable prognosis of
coronavirus disease 2019 (COVID-19) is critical in protecting vulnerable individuals …

Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The
diagnosis between COVID-19-induced pneumonia and immunotherapy-induced …